LIST OF CLINICAL TRIALS

Search for clinical trials open in our centers by cancer type.

PLEASE MAKE A SELECTION TO
BROWSE RESULTS

OPEN TRIAL CLOSED TRIAL

BREAST CANCER

POSITIVE [OPEN TRIAL]

Study to evaluate the effect of pregnancy and the safety of interupting endocrine treatment in young women with breast cancer responding to endocrine treatment who wish to become pregnant. Protocol: IBCSG 48‐14 / BIG 8‐13

+ INFO

LUNG AND PLEURAL CANCER

PTEROSTILBENE [OPEN TRIAL]

Observational study in patients treated with EGFR/IT inhibitors and pterostilbene.

+ INFO

SOLID TUMORS

PUMA [OPEN TRIAL]

An open-label, phase 2 study of Neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification.

+ INFO

LUNG AND PLEURAL CANCER

SELINA [OPEN TRIAL]

Analysis of soluble mediators, cytokines, and circulating angiogenic factors (CAFs) as potential predictors / prognostic factors in antiangiogenic treatment after failure of first-line chemotherapy in advanced non-squamous lung carcinoma.

+ INFO

BREAST CANCER

SHERBOC [OPEN TRIAL]

A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy. Protocol: MM-121-02-02-10.

+ INFO

SOLID TUMORS

SYM015 [OPEN TRIAL]

An open-label, multicenter phase 1a/2a trial investigating the safety, tolerability and antitumor activity of multiple doses of Sym015, a monoclonal antibody mixture targeting MET, in patients with advanced solid tumor malignancies.

+ INFO

LUNG AND PLEURAL CANCER

VISION [OPEN TRIAL]

Single group, phase II trial to investigate tepotinib in pulmonary adenocarcinoma in stage IIIB / IV with alterations by omission of exon 14 of MET (METex14) after failure to at least one previous active treatment, including one with platinum doublet. Protocol: MS200095-002

+ INFO

LUNG AND PLEURAL CANCER

X396-CLI-301 [OPEN TRIAL]

Phase III randomized study comparing X-396 vs crizotinib in patients with non small cell lung cancer (NSCLC) positive for the anaplastic lymphoma kinase (ALK).

+ INFO